Miklós Szabó, László Hajba, Renáta Kun, András Guttman* and Eszter Csánky Pages 3302 - 3313 ( 12 )
Lung adenocarcinoma is one of the leading causes of mortality among cancer patients worldwide and Chronic Obstructive Pulmonary Disease (COPD) is also high in death statistics. In addition, patients with Chronic Obstructive Pulmonary Disease (COPD) have a high risk of developing primary lung cancer. Prevention, risk estimation and a non-invasive diagnostics are essential to decrease COPD and lung cancer mortality. Therefore, better and more accurate molecular diagnostic markers (biomarkers) are needed for the early differential diagnosis of these lung diseases to help clinicians make better therapeutic decisions. This review focuses on recently discovered adenocarcinoma and COPD biomarkers at the proteome and glycome level. In the first part, the protein markers are summarized, while the second part is focused on glycan markers. Their use to differentiate between chronic inflammation (COPD) and malignant (adenocarcinoma) diseases is discussed in detail.
Lung cancer, lung adenocarcinoma, COPD, molecular markers, proteomics, glycomics.
Department of Pulmonology, Semmelweis Hospital, of Borsod Abauj Zemplen County Central Hospital and University Teaching Hospital Department of Pulmonology, Miskolc, Translational Glycomics Research Group, Research Institute for Biomolecular and Chemical Engineering, University of Pannonia, Veszprem, Horvath Csaba Laboratory of Bioseparation Sciences, Research Centre for Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Translational Glycomics Research Group, Research Institute for Biomolecular and Chemical Engineering, University of Pannonia, Veszprem, Department of Pulmonology, Semmelweis Hospital, of Borsod Abauj Zemplen County Central Hospital and University Teaching Hospital Department of Pulmonology, Miskolc